Occam Dx
About Occam Dx
The impossible made simple!Conventional microbiology requires laborious amplification to even detect anything. We are the first to introduce a technology that is sensitive enough to simply count the pathogens one by one directly from the sample. Thanks to our patented nano-electronic biosensor, we are able to detect even one single virus or bacterium, resulting in unprecedented sensitivity. We identify the targeted pathogen and disregard other components in the sample, for superior specificity. This gives you better insights to make the right diagnosis and determine the correct regimen.The test is performed as close as possible to the patient. The data is brought as close as possible to the clinician, through the cloud. This ensures a secure mode of communication between the medical professional in the ER, OR, ICU and GP's office and the microbiologist in the lab.We significantly reduced the logistical complexity of a diagnosis. Less hands-on time, easy-to-use for all practitioners, online accessible, resulting in an effective and cost efficient procedure.
Company Metrics
- Employees: 1-10
- Monthly Visits: None
- Tech Stack: None active products
Financial Information
- Estimated Revenue: Not available
- Total Funding: None None
- Last Funding: None None (None)
- Funding Status: None
Technology Stack
Occam Dx actively uses None products in their tech stack.
Market Presence
Industries: Nanotechnology, Nanotechnology, Nanotechnology research
Headquarters: Enschede, Overijssel